tiprankstipranks
Advertisement
Advertisement

CNTX Stock Latest News

Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
RatingsAnalyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
7d ago
CNTX
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
PremiumRatings
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
8d ago
CNTX
Context Therapeutics Secures Full Rights to Antibody Assets
PremiumCompany Announcements
Context Therapeutics Secures Full Rights to Antibody Assets
9d ago
8K
CNTX
Context Therapeutics enters license agreement amendment with BioAtla
PremiumThe Fly
Context Therapeutics enters license agreement amendment with BioAtla
9d ago
BCAB
CNTX
Context Therapeutics Maintained at Buy as Advancing Clinical Pipeline and Upcoming Catalysts Support Unchanged $5 Price Target
PremiumRatings
Context Therapeutics Maintained at Buy as Advancing Clinical Pipeline and Upcoming Catalysts Support Unchanged $5 Price Target
20d ago
CNTX
Context Therapeutics reports Q1 EPS (9c), consensus (12c)
PremiumThe FlyContext Therapeutics reports Q1 EPS (9c), consensus (12c)
20d ago
CNTX
Context Therapeutics settles governance lawsuit with mootness fee
Premium
Company Announcements
Context Therapeutics settles governance lawsuit with mootness fee
25d ago
8K
CNTX
Buy Rating Reiterated on Context Therapeutics as CTIM-76 T-Cell Engager Progress Supports Unchanged $5 Price Target
Premium
Ratings
Buy Rating Reiterated on Context Therapeutics as CTIM-76 T-Cell Engager Progress Supports Unchanged $5 Price Target
28d ago
CNTX
Context Therapeutics: Anticipated CTIM-76 Ovarian Cancer Data as a Key Catalyst for CNTX Re-Rating
PremiumRatings
Context Therapeutics: Anticipated CTIM-76 Ovarian Cancer Data as a Key Catalyst for CNTX Re-Rating
1M ago
CNTX
Advancing Bispecific T‑Cell Engager Pipeline and Regulatory Milestones Underpin Buy Rating on Context
PremiumRatings
Advancing Bispecific T‑Cell Engager Pipeline and Regulatory Milestones Underpin Buy Rating on Context
2M ago
CNTX
3 Best Stocks to Buy Today, 4/3/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 4/3/2026, According to Top Analysts
2M ago
AVNW
CNTX
Context Therapeutics Gains FDA Fast Track for CTIM-76
PremiumCompany Announcements
Context Therapeutics Gains FDA Fast Track for CTIM-76
2M ago
8K
CNTX
Context Therapeutics granted Fast Track Designation to CTIM-76 by FDA
PremiumThe FlyContext Therapeutics granted Fast Track Designation to CTIM-76 by FDA
2M ago
CNTX
Context Therapeutics: Advancing T‑Cell Engager Pipeline and De‑Risked Cash Runway Support a Buy Rating
Premium
Ratings
Context Therapeutics: Advancing T‑Cell Engager Pipeline and De‑Risked Cash Runway Support a Buy Rating
2M ago
CNTX
Context Therapeutics price target raised to $7 from $4 at Piper Sandler
Premium
The Fly
Context Therapeutics price target raised to $7 from $4 at Piper Sandler
2M ago
CNTX
Context Therapeutics Highlights Evolving T Cell Engager Pipeline
PremiumCompany Announcements
Context Therapeutics Highlights Evolving T Cell Engager Pipeline
2M ago
8K
CNTX
CNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CNTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
CNTX
Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes
PremiumCompany Announcements
Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes
2M ago
8K
CNTX
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections
PremiumCompany Announcements
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections
3M ago
8K
CNTX
Context Therapeutics Highlights T Cell Engager Pipeline Strategy
PremiumCompany AnnouncementsContext Therapeutics Highlights T Cell Engager Pipeline Strategy
5M ago
8K
CNTX
Context Therapeutics initiated with a Buy at JonesResearch
Premium
The Fly
Context Therapeutics initiated with a Buy at JonesResearch
5M ago
CNTX
Buy Rating for Context Therapeutics: Strong Financials and Promising Clinical Developments
Premium
Ratings
Buy Rating for Context Therapeutics: Strong Financials and Promising Clinical Developments
7M ago
CNTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >